Navigation Links
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Date:9/8/2010

PARIS and TARRYTOWN, N.Y., Sept. 8 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns.  This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.  Both sanofi-aventis and Regeneron management and staff remain blinded to the interim study results.

"We look forward to the final results of the trial, which are expected in the second half of 2011 with belief that the combination of aflibercept and FOLFIRI has the potential to benefit patients with this difficult-to-treat disease," said Tal Zaks, Head of Development, Global Oncology Division, sanofi-aventis.

About the VELOUR StudyThe main objective of the VELOUR (Aflibercept Versus Placebo in Combination with Irinotecan and 5-FU [FOLFIRI] in the Treatment of Patients with Metastatic Colorectal Cancer after Failure of an Oxaliplatin Based Regimen) study is to evaluate the safety and effectiveness of aflibercept as a second-line treatment in combination with folinic acid (leucovorin), 5-fluorouracil, and irinotecan (FOLFIRI) in 1,226 patients with mCRC who previously had been treated with an oxaliplatin-based regimen.  The primary endpoint is improvement in overall survival.  Secondary endpoints include progression-free survival, response to treatment, and safety.

About the Aflibercept Clinical Development ProgramSanofi-aventis Oncology and Regeneron are collaborating on a broad oncology development program combining aflibercept (VEG
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Robert E. Marc, Ph.D., director of research at the ... been named by the International Society of Eye Research ... Research Foundation,s 2014 Paul Kayser International Award in Retina ... scientist who has made a significant contribution to the ... being presented this week at the ISER Biennial Meeting ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
(Date:7/22/2014)... The 6th Latin American Conference on Lung Cancer (LALCA ... in Lima, Peru. , Lung Cancer is still the ... but worldwide. Building on the success of the previous ... national speakers will discuss the science and advances in ... malignancies worldwide and Latin America in particular. , With ...
(Date:7/22/2014)... 2014 The Entertainment Industries Council, Inc. ... educational tools and recognition activities for thousands of entertainment ... treatment and recovery. On July 24, 2014, at 8pm, ... of these resources with a special mention of the ... treatment website at the end of the show. ...
(Date:7/22/2014)... Doheny HealthDay Reporter TUESDAY, ... a minimally invasive procedure known as morcellation carries a risk ... the likelihood more clearly. Twenty-seven of every 10,000 women ... time of the procedure, researchers found, with the odds being ... performing a hysterectomy with morcellation use a power cutter to ...
Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3
... Health Care Budget Reform and Transparency Act of 2009 ... Government Employees, today, lauded the efforts of Congress in passing ... provided by the Department of Veterans Affairs. For more than ... VA funding process. AFGE applauds these members of Congress for ...
... will host "S,more to Love", a cocktail fundraiser on Friday, November ... benefit Birch Family Camp. , Celebrating its 20th year, the Birch ... the 5 boroughs of NYC, along with 200 volunteers for a ... located in the Hudson Valley. Throughout the year this community ...
... Health and Wellness Partners, Inc. (HWP), a wholly owned subsidiary ... line of nutraceutical products called Surge, www.feelthesurge.com ... world to develop and refine production of the product line. ... "We placed our first large production order with one of ...
... companies have been doing it for years. Why not ... thoughtful discussion in hospitals and as a way to ... secondary markets. One developer, North Carolina-based Oaks ... medical office buildings (MOBs). As such, the innovative developer ...
... in Cell Cultures and in Patients , PHILADELPHIA, ... to The Children,s Hospital of Philadelphia Research Institute will ... HIV infection -- a unique class of drugs focused ... AIDS. , Unlike many current HIV treatments, which ...
... University of Rochester Medical Center demonstrates that, for certain ... may be a cost effective treatment. The implantable ... for individuals with drug resistant hypertension. The ... Journal of Clinical Hypertension used data from ...
Cached Medicine News:Health News:VA Funding Reform Bill Clears Congress 2Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 2Health News:Health and Wellness Partners, Inc., Says to America 'Feel the Surge' 3Health News:Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:Cost effectiveness of blood pressure device evaluated 2Health News:Cost effectiveness of blood pressure device evaluated 3
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: